Beijing Kawin Technology Share-holding Co Ltd (688687) - Total Assets

Latest as of March 2026: CN¥2.70 Billion CNY ≈ $394.79 Million USD

Based on the latest financial reports, Beijing Kawin Technology Share-holding Co Ltd (688687) holds total assets worth CN¥2.70 Billion CNY (≈ $394.79 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 688687 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Beijing Kawin Technology Share-holding Co Ltd - Total Assets Trend (2008–2025)

This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's total assets have evolved over time, based on quarterly financial data. Check 688687 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Beijing Kawin Technology Share-holding Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Beijing Kawin Technology Share-holding Co Ltd's total assets of CN¥2.70 Billion consist of 70.0% current assets and 30.0% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 29.9%
Accounts Receivable CN¥441.37 Million 15.8%
Inventory CN¥136.01 Million 4.9%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥71.48 Million 2.6%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2008–2025)

This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beijing Kawin Technology Share-holding C market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Beijing Kawin Technology Share-holding Co Ltd's current assets represent 70.0% of total assets in 2025, an increase from 30.9% in 2008.
  • Cash Position: Cash and equivalents constituted 29.9% of total assets in 2025, down from 30.9% in 2008.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2008.
  • Asset Diversification: The largest asset category is accounts receivable at 15.8% of total assets.

Beijing Kawin Technology Share-holding Co Ltd Competitors by Total Assets

Key competitors of Beijing Kawin Technology Share-holding Co Ltd based on total assets are shown below.

Company Country Total Assets
Samsung Biologics Co Ltd
KO:207940
Korea ₩18.34 Trillion
Royalty Pharma Plc
NASDAQ:RPRX
USA $19.82 Billion
Abivax SA
PA:ABVX
France €584.34 Million
Verona Pharma PLC ADR
NASDAQ:VRNA
USA $572.87 Million
HLB Co. Ltd
KQ:028300
Korea ₩703.48 Billion
Chongqing Zhifei Bio Products
SHE:300122
China CN¥29.09 Billion
Neuren Pharmaceuticals Ltd
AU:NEU
Australia AU$331.25 Million
Theravance Biopharma Inc
F:0TB
Germany €415.46 Million

Beijing Kawin Technology Share-holding Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.01 4.33 5.52
Quick Ratio 2.81 3.94 5.13
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.25 Billion CN¥1.36 Billion CN¥1.30 Billion

Beijing Kawin Technology Share-holding Co Ltd - Advanced Valuation Insights

This section examines the relationship between Beijing Kawin Technology Share-holding Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.00
Latest Market Cap to Assets Ratio 0.15
Asset Growth Rate (YoY) 6.8%
Total Assets CN¥2.79 Billion
Market Capitalization $415.24 Million USD

Valuation Analysis

Below Book Valuation: The market values Beijing Kawin Technology Share-holding Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Beijing Kawin Technology Share-holding Co Ltd's assets grew by 6.8% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Beijing Kawin Technology Share-holding Co Ltd (2008–2025)

The table below shows the annual total assets of Beijing Kawin Technology Share-holding Co Ltd from 2008 to 2025.

Year Total Assets Change
2025-12-31 CN¥2.79 Billion
≈ $408.72 Million
+6.79%
2024-12-31 CN¥2.62 Billion
≈ $382.75 Million
+6.84%
2023-12-31 CN¥2.45 Billion
≈ $358.25 Million
+10.79%
2022-12-31 CN¥2.21 Billion
≈ $323.35 Million
+1.47%
2021-12-31 CN¥2.18 Billion
≈ $318.67 Million
+85.78%
2020-12-31 CN¥1.17 Billion
≈ $171.53 Million
+11.37%
2019-12-31 CN¥1.05 Billion
≈ $154.02 Million
+29.21%
2018-12-31 CN¥814.56 Million
≈ $119.20 Million
+12.57%
2017-12-31 CN¥723.61 Million
≈ $105.89 Million
+4.08%
2015-12-31 CN¥695.21 Million
≈ $101.73 Million
+58.28%
2014-12-31 CN¥439.24 Million
≈ $64.27 Million
+8.82%
2013-12-31 CN¥403.63 Million
≈ $59.06 Million
+28.98%
2012-12-31 CN¥312.94 Million
≈ $45.79 Million
+48.97%
2011-12-31 CN¥210.07 Million
≈ $30.74 Million
+27.46%
2010-12-31 CN¥164.82 Million
≈ $24.12 Million
+136.95%
2009-12-31 CN¥69.56 Million
≈ $10.18 Million
+117.36%
2008-12-31 CN¥32.00 Million
≈ $4.68 Million
--

About Beijing Kawin Technology Share-holding Co Ltd

SHG:688687 China Biotechnology
Market Cap
$415.24 Million
CN¥2.84 Billion CNY
Market Cap Rank
#13388 Global
#4024 in China
Share Price
CN¥16.60
Change (1 day)
+1.59%
52-Week Range
CN¥15.95 - CN¥38.59
All Time High
CN¥40.56
About

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more